Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Sanofi Files Patent Lawsuit Against Moderna Over mRNA Vaccine Technology

    Sanofi has filed a patent infringement lawsuit against Moderna in the U.S. District Court for the District of New Jersey, alleging that Moderna's mRNA vaccine technologies infringe a portfolio of patents originally developed by Translate Bio, a biotechnology company acquired by Sanofi in 2021. The complaint names Translate Bio, Translate Bio MA, Sanofi Vaccines US, and VaxServe as plaintiffs, while Moderna, ModernaTX, and Moderna US are listed as defendants.

  • FDA Approves First Generic Afatinib Tablets for Lung Cancer; Apotex and Hetero Secure U.S. Approval
    FDA Approves First Generic Afatinib Tablets for Lung Cancer; Apotex and Hetero Secure U.S. Approval
    The U.S. Food and Drug Administration (FDA) has approved the first generic versions of GILOTRIF (afatinib) tablets, marking an important milestone in expanding access to targeted therapy for patients with specific forms of non-small cell lung cancer (NSCLC). The approval covers generic afatinib tablets manufactured by Apotex Inc. and Hetero Labs Limited Unit V.
  • FDA Flags Medtronic Pulmonary Valve Delivery System Recall as Class I Over Risk of Catheter Tip Detachment
    FDA Flags Medtronic Pulmonary Valve Delivery System Recall as Class I Over Risk of Catheter Tip Detachment

    The U.S. Food and Drug Administration (FDA) has announced a Class I recall, its most serious recall category, for certain Medtronic Harmony™ Delivery Catheter Systems (DCS) used to implant transcatheter pulmonary valves. The recall follows concerns that a manufacturing defect could cause the catheter's distal tip to detach during implantation, potentially leading to serious complications, including emergency surgery or death.

  • FDA Approves First At-Home Starting Dose for Alzheimer's Therapy, Expanding Access to Early Treatment
    FDA Approves First At-Home Starting Dose for Alzheimer's Therapy, Expanding Access to Early Treatment

    The U.S. Food and Drug Administration (FDA) has approved the first at-home starting dose for an Alzheimer's disease treatment, marking a significant advancement in the management of early Alzheimer's disease. The approval allows eligible patients to begin therapy using a subcutaneous (under-the-skin) injection at home, either by self-administration or with the assistance of a caregiver, reducing the need for hospital or infusion-center visits.

  • IPA Seeks High-Level Probe into Delhi Pharmacy Council, Cites Governance Concerns and Registration Delays
    IPA Seeks High-Level Probe into Delhi Pharmacy Council, Cites Governance Concerns and Registration Delays

    The Indian Pharmacist Association (IPA) has written to the Lieutenant Governor of Delhi seeking a high-level independent inquiry into the functioning of the Delhi Pharmacy Council (DPC). In a letter dated 12 July 2026, the association requested immediate intervention, alleging that administrative shortcomings and prolonged registration delays are adversely affecting pharmacy students and registered pharmacists.

  • Scientists Discover Hepatitis E Virus Begins Evolving Within Weeks of Infection
    Scientists Discover Hepatitis E Virus Begins Evolving Within Weeks of Infection

    Researchers from Ruhr University Bochum, Germany, have uncovered new evidence showing that the hepatitis E virus (HEV) begins evolving much earlier during infection than previously understood. The findings, published in the journal mBio, reveal that although the virus exhibits relatively low genetic diversity during the acute phase, it rapidly acquires specific recurring mutations within just a few weeks of infection. The discovery offers new insights into how HEV adapts inside the human body and could help guide future antiviral research.

  • Emcure Takes Full Control of Gennova, Bets Big on Biologics and Biosimilars Under New Leadership
    Emcure Takes Full Control of Gennova, Bets Big on Biologics and Biosimilars Under New Leadership

    Emcure Pharmaceuticals Limited has announced a major strategic restructuring of its biopharmaceutical business by acquiring the remaining 12.05% minority stake in Gennova Biopharmaceuticals Limited, making it a wholly owned subsidiary. The company also announced a leadership transition, appointing Samit Mehta to lead Gennova as it sharpens its focus on biologics, biosimilars, and next-generation therapeutic platforms.

  • Government Brings High-Alcohol Oral Medicines Under Schedule H1 with New Drugs Rules Amendment
    Government Brings High-Alcohol Oral Medicines Under Schedule H1 with New Drugs Rules Amendment

    In a significant move to strengthen the regulation of certain medicinal products, the Ministry of Health and Family Welfare has notified the Drugs (Tenth Amendment) Rules, 2026, bringing specific high-alcohol oral formulations under the stricter provisions of Schedule H1 of the Drugs Rules, 1945.

  • Novo Nordisk Launches World's First Once-Weekly Insulin 'Awiqli' in India
    Novo Nordisk Launches World's First Once-Weekly Insulin 'Awiqli' in India

    Danish pharmaceutical giant Novo Nordisk has launched Awiqli (insulin icodec) in India, introducing the world's first once-weekly basal insulin for adults with Type 1 and Type 2 diabetes. The launch marks a major advancement in diabetes care by reducing the number of insulin injections from 365 per year to just 52, potentially improving treatment adherence among millions of patients.

  • FDA Proposes Landmark Drug Registration Reforms : What the New Rules Mean for Global Pharma and India
    FDA Proposes Landmark Drug Registration Reforms : What the New Rules Mean for Global Pharma and India

    The U.S. Food and Drug Administration (FDA) has proposed a major overhaul of its drug establishment registration and drug listing regulations, aiming to modernize oversight of pharmaceutical manufacturing and improve visibility across global supply chains. If finalized, the rule would introduce a new regulatory framework for distributed manufacturing and expand registration requirements for certain foreign drug manufacturing establishments that currently fall outside existing regulations.

Subscribe to Pharma News